17702-11-3

Usage

Chemical Properties

clear colorless to light yellow liquid

InChI:InChI=1/C5H9NOS/c1-7-4-2-3-6-5-8/h2-4H2,1H3

Upstream product

• 75-15-0 carbon disulfide 
• 5332-73-0 3-methoxypropylamine 
• 463-71-8 thiophosgene 

Downstream Products

• 1443334-66-4 4-chloro-3-(4-cyclopropylbenzyl)-1-(6-deoxy-6-{[(3-methoxypropyl)carbamothioyl]-amino}-β-D-glucopyranosyl)-1H-indole 
• 1428668-53-4 methyl 1-(3,3-diphenylpropyl)-2-{2-[(3-methoxypropyl)amino]-1,3-benzothiazol-7-yl}-1H-benzimidazole-5-carboxylate 
• 1428668-52-3 methyl 2-{2-[(3-methoxypropyl)amino]-1,3-benzothiazol-7-yl}-1-(3-phenylpropyl)-1H-benzimidazole-5-carboxylate 
• 1404054-00-7 2,7-bis(4-hydroxy-3-methoxyphenyl)-8-(3-methoxypropyl)-7,8-dihydro-2H-thiopyrano[2,3-b]pyridine-4,5(3H,6H)-dione 
• 1404053-97-9 C₂₆H₂₉NO₇S 
• 1404053-96-8 2,7-bis(4-hydroxy-3-methoxyphenyl)-8-(3-methoxypropyl)-7,8-dihydro-4H-thiopyrano[2,3-b]pyridine-4,5(6H)-dione 
• 850219-17-9 3-(3-methoxy-propyl)-5,5-diphenyl-2-thioxo-imidazolidin-4-one 
• 66892-33-9 N-(1-methoxy)propyl thiourea 

Relevant academic research and scientific papers

Rigidified Compounds for Modulating Heparanase Activity

Disclosed are novel rigidified compounds having a rhodanine-like residue and at least one aryl or heteroaryl residue linked to the rhodanine-like residue, whereby a core structure of these compounds, as defined in the specification, is characterized as having one or zero free-to-rotate bonds. Also disclosed are pharmaceutical compositions containing these rigidified compounds and uses thereof for modulating the activity of heparanase and hence in the treatment of heparanase-associated diseases and disorders, and uses thereof for modulating the activity of heparin-binding proteins and hence in the treatment of heparin-binding proteins-associated diseases and disorders as well as in the treatment of medical conditions that are at least partially treatable by rhodanine or a rhodanine analog.

Substituted 5,5′-diphenyl-2-thioxoimidazolidin-4-one as CB 1 cannabinoid receptor ligands: Synthesis and pharmacological evaluation

A set of 30 substituted 5,5′-diphenyl-2-thioxoimidazolidin-4-one (thiohydantoins) derivatives was synthesized, and their affinity for the human CB1 cannabinoid receptor has been evaluated. These compounds are derived from the previously described cannabinoid ligands 5,5′- diphenylimidazolidine-2,4-dione (hydantoins). The replacement of the oxygen by a sulfur leads to an increase of the affinity while the function-i.e., inverse agonism-determined by [35S]-GTPγS experiments remains unaffected. Finally, to evaluate the molecular parameters that could influence the affinity of the thiohydantoins, molecular electrostatic potential as well as lipophilicity calculations were undertaken on representative thiohydantoins and hydantoins derivatives. In conclusion, 5,5′-bis-(4-iodophenyl)-3-butyl-2- thioxoimidazolidin-4-one (31) and 3-allyl-5,5′-bis(4-bromophenyl)-2- thioxoimidazolidin-4-one (32) possess the highest affinity for the CB 1 cannabinoid receptor described to date for the hydantoin and thiohydantoins series when compared in a same bioassay.